Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025Open Access

Supplementary Figure S2 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiyi WangYZYu ZhangXLXiangdong Li

Discussion

Loading...

Member takes

Overview

This analysis demonstrates that myeloid Trem2 influences CD9+NAM differentiation, highlighting its role in immunotherapy.

Key Points

  • Myeloid Trem2 promotes CD9+NAM differentiation, enhancing the response to immunotherapy in NASH-driven hepatocarcinogenesis.
  • Evidence shows that targeting Trem2 reprograms the immunosuppressive niche, providing a new therapeutic avenue.
  • The study utilizes observational analysis to assess the impact of Trem2 on immune cell differentiation.
  • These findings suggest that targeting Trem2 could improve patient outcomes in liver cancer driven by NASH.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219bchttps://doi.org/10.1158/2326-6066.30255490
View Full Paper
Ask AI
Bookmark
Share